A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants
Status:
Withdrawn
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether lanabecestat can be safely prescribed in
participants with kidney impairment without a dose adjustment.
Participants will be on study for up to 6 weeks; this includes a 2-week screening and a
follow-up about 10 days after final drug administration.